Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

In conclusion, patients with relapsed or refractory multiple myeloma who received carfilzomib‐containing regimens had improved PFS and ORR compared with control groups, regardless of whether they had an early or late relapse following the most recent prior therapy.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhon.2499

Source: Hematological Oncology - December 1, 2017 Category: Hematology Authors: Maria ‐Victoria Mateos, Hartmut Goldschmidt, Jesus San‐Miguel, Joseph Mikhael, Lucy DeCosta, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, Xavier Leleu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research